SUPPLY AGREEMENTSupply Agreement • October 11th, 2019 • SutroVax, Inc. • Biological products, (no disgnostic substances) • California
This SUPPLY AGREEMENT (“Supply Agreement”) is made as of May 29, 2018 (the “Effective Date”) by and between SutroVax, Inc., a Delaware corporation having principal offices at 353 Hatch Dr., Foster City, CA 94404 (“SutroVax”) and Sutro Biopharma, Inc., a Delaware corporation, having principal offices at 310 Utah Ave, Suite 150, South San Francisco, CA, 94080 (“Sutro”). SutroVax and Sutro may be referred to herein by name or individually, as a “Party” and collectively, as the “Parties.”
AMENDED AND RESTATED SUTROVAX AGREEMENTSutrovax Agreement • October 11th, 2019 • SutroVax, Inc. • Biological products, (no disgnostic substances) • California
This Amended and Restated SutroVax Agreement (this “Agreement”), is made effective as of October 12, 2015 (the “Amendment Effective Date”), by and between Sutro Biopharma, Inc., having its principal place of business at 310 Utah Ave, Suite 150, South San Francisco, CA 94080 (“Sutro”), and SutroVax, Inc., having a principal place of business at 400 East Jamie Ct, Suite 205, South San Francisco CA 94080 (“SutroVax”), each a “Party” and collectively “Parties”, and amends and restates in its entirety that certain SutroVax Agreement, dated August 1, 2014 (the “Effective Date”), by and between Sutro and SutroVax (the “Original Agreement”).
DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT (the “Agreement”)Development and Manufacturing Services Agreement • October 11th, 2019 • SutroVax, Inc. • Biological products, (no disgnostic substances) • Delaware
WHEREAS, Customer is engaged in the development and research of certain products and requires assistance in the development and manufacture of product:
Development and Manufacturing Services Agreement (the “Agreement”)Original Agreement • October 11th, 2019 • SutroVax, Inc. • Biological products, (no disgnostic substances)
WHEREAS, Customer is engaged in the development and research of certain products and requires assistance in the development and manufacture of product;
LICENSE AGREEMENTLicense Agreement • October 11th, 2019 • SutroVax, Inc. • Biological products, (no disgnostic substances) • California
This agreement (“Agreement”) is entered into as of the date of last signature (the “Effective Date”) by and between SutroVax, Inc. a Delaware corporation having an address at 353 Hatch Drive, Foster City, California 94404 (“LICENSEE”) and The Regents of the University of California, a California public corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University of California San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UC SAN DIEGO”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. Lonza Ltd Münchensteinerstrasse 38 CH-4002 Basel...SutroVax, Inc. • October 11th, 2019 • Biological products, (no disgnostic substances)
As you know, Lonza Ltd (“Lonza”) and SutroVax, Inc (“SutroVax” or “Customer”) are parties to the Development and Manufacturing Services Agreement, dated October 21, 2016, between Lonza and SutroVax and as amended on January 1, 2017, July 1, 2017 and September 26, 2017 (the “2016 Agreement”), under which Lonza is providing development and manufacturing services to SutroVax in connection with SutroVax’s multi-valent pneumococcal vaccine product. In addition, as of the date of this letter, SutroVax and Lonza are in negotiations of a new Development and Manufacturing Services Agreement, which, if entered into, will govern the terms and conditions under which Lonza will provide SutroVax with development and manufacturing services for such vaccine product in drug product form (the “2018 Agreement”). The 2016 Agreement, the 2018 Agreement, and any future written addendums and agreements entered into between SutroVax and Lonza relating to SutroVax’s engagement of Lonza’s services for SutroVax’
THIRD ADDENDUM TO STANDARD MULTI-TENANT OFFICE LEASE – NET DATED SEPTEMBER 16, 2016SutroVax, Inc. • October 11th, 2019 • Biological products, (no disgnostic substances)
In the event of any conflict between the provisions of this Addendum and the printed provisions of the Lease, this Addendum shall control.
STANDARD NNN LEASE [MULTI-TENANT PROJECT]NNN Lease • October 11th, 2019 • SutroVax, Inc. • Biological products, (no disgnostic substances)
